Pharma Pulse: A Rare Disease Drug Approval and the Evolving Scope of Pharmacy Practice

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.

• The FDA has granted expanded approval for Imcivree (setmelanotide), the first treatment for acquired hypothalamic obesity. This rare condition, often caused by brain injury or tumors, disrupts the MC4R pathway, leading to severe, unrelenting weight gain. In Phase III trials, patients achieved an 18.4% placebo-adjusted BMI reduction, providing a targeted option where none previously existed.
• Next, research shows optimizing pharmacy technician roles significantly boosts vaccine uptake. Using a "high efficiency" model with technician injectors reduces dispensing errors and allows pharmacists to focus on clinical tasks like chronic disease management. This practice is now supported by permanent legislation in 47 states.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.